[Evaluation of the therapeutic effects of broncaspin in chronic bronchopneumopathies]

A controlled single-blind clinical trial was made with Broncaspin, on original synthetic molecule obtained by condensing acetylsalicylic acid and guaiacol, in a comparison of its local and general tolerance, and antipyretic, antiexudative and balsamic properties with those of dimethylaminophenazone guaiacolglycolate, a well-known preparation, in two randomly composed groups of 15 patients with chronic obstructive bronchial and lung diseases, using 1,2 g Broncaspin suppositories and the commercial form of the other product twice a day for 14 consecutive days. Therapeutic assessment was based on the symptomatological, spirometric and blood gas data.